Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis

review OA: closed CC0 ⤵ 1 in-corpus citation
AI-generated summary by claude@2026-06, 2026-06-08

This review examines new pharmaceutical products targeting hormonal pathways, vascularization, and implantation for endometriosis treatment and discusses related recent patents.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-09 · read from full text

The paper reviews endometriosis pathophysiology, describing ectopic endometrial-like implants that proliferate and bleed cyclically, driving inflammatory pain and potentially infertility through hormonal, cytokine, and chemokine–related mechanisms. It summarizes existing long-used anti-inflammatory and gonadotropin-releasing hormone agonist therapies, then focuses on newer pharmaceutical strategies aimed at suppressing hormonal-mediated cell growth (e.g., via estrogen/androgen metabolic pathway inhibition), reducing vascularization, and targeting implantation/engraftment. The review highlights classes of agents and molecular targets including selective estrogen, androgen, and progesterone receptor modulators, aromatase inhibitors, VEGF receptor inhibitors, and extracellular matrix modulators, alongside a brief discussion of related patents. This paper is centrally about endometriosis — it reviews recent knowledge and emerging pharmaceutical product targets for alleviating endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is so far considered as an incurable inflammatory disease. The ectopical implants of endometrial cells proliferate, increase in size and thereafter bleed following the menstrual cycle. The accumulated blood aggravates the situation by developing into cysts which, depending on the place, size and number, in most cases increase pain. Infertility in endometriosis is related either to mechanical distortion of the reproductive truck or to various endometriosis-induced factors including hormones, cytokines and chemokines. Except from the anti-inflammatory treatments and gonadotropin-releasing hormone agonists that have been used for a long time to relief from pain, new treatments are targeted against either hormonal-mediated cell growth via inhibition of the metabolic pathway of estrogens and androgens or vascularization or even implantation of the endometrial engraftment. Thus, the role of selective estrogen, androgen or progesterone receptor modulators, aromatase inhibitors, vascular endothelial growth factor receptor and extracellular matrix modulators is reviewed. This article also reviewed recent patents related to the field.
Full text 1,298 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Endometriosis is so far considered as an incurable inflammatory disease. The ectopical implants of endometrial cells proliferate, increase in size and thereafter bleed following the menstrual cycle. The accumulated blood aggravates the situation by developing into cysts which, depending on the place, size and number, in most cases increase pain. Infertility in endometriosis is related either to mechanical distortion of the reproductive truck or to various endometriosis-induced factors including hormones, cytokines and chemokines. Except from the anti-inflammatory treatments and gonadotropinreleasing hormone agonists that have been used for a long time to relief from pain, new treatments are targeted against either hormonal-mediated cell growth via inhibition of the metabolic pathway of estrogens and androgens or vascularization or even implantation of the endometrial engraftment. Thus, the role of selective estrogen, androgen or progesterone receptor modulators, aromatase inhibitors, vascular endothelial growth factor receptor and extracellular matrix modulators is reviewed. This article also reviewed recent patents related to the field.

Keywords

Endometriosis, estrogen receptor agonists, androgen receptor agonists, VEGF receptor inhibitors, cytokines, immune system 6

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

MeSH descriptors

Endometriosis Receptors, Androgen Receptors, Estrogen Animals Aromatase Inhibitors Aromatase Inhibitors Endometriosis Endometriosis Endometriosis Female Humans Patents as Topic Receptors, Androgen Receptors, Estrogen Receptors, Progesterone Receptors, Progesterone Receptors, Vascular Endothelial Growth Factor Receptors, Vascular Endothelial Growth Factor

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-08-01T06:07:04.264727+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:18.065553+00:00
License: CC0 · commercial use OK